From the TAPS Tool: In the PAST 12 MONTHS, how often have you used any drugs including marijuana, cocaine or crack, heroin, methamphetamine (crystal meth), hallucinogens, ecstasy/MDMA?
1. Daily or almost daily (displayed as "0"): a subjective response that something happens daily or almost daily
2. Weekly (displayed as "1"): Every week
3. Monthly (displayed as "2"): Every month
4. Less than Monthly (displayed as "3"): An event that occurs less frequently than once a month
5. Never (displayed as "4"): Not ever, at no time in the past (or future).
|Submitted By: Jessica Cotto / National Institute on Drug Abuse|
|Data Element Information|
|Use Case Description(s)|
|Use Case Description||According to the 2019 National Survey on Drug Use and Health (NSDUH), 20.2% of people ages 12 or older reported past month cigarette use. In addition, 8.1% reported past month cigar use, 4.2% used smokless tobacco and 13% used illicit drugs. In total, nearly 36 million people ages 12 or older reported past month use of illicit drugs in 2019 and 58 million reported use of tobacco in the past month.|
|Estimated number of stakeholders capturing, accessing using or exchanging||U.S. primary health care providers: The U.S. Preventive Services Task Force (USPSTF) recommends screening for unhealthy drug use in adults aged 18 years and older, with a Grade B recommendation:
|Link to use case project page||https://www.samhsa.gov/data/report/2019-nsduh-annual-national-report The National Survey on Drug Use and Health.|
|Maturity of Use and Technical Specifications for Data Element|
|Applicable Standard(s)||Elements were recently submitted for inclusion in LOINC.
|Additional Specifications||NIDA Screening Tools API Gateway, TAPS API found at: https://api.drugabuse.gov/prod/taps/
|Current Use||This data element has been used at scale between multiple different production environments to support the majority of anticipated stakeholders|
This data element has been used at scale and reviewed for maximum stakeholder impact. Our internal analysis of web traffic to the TAPS website (https://www.drugabuse.gov/taps/ ) in Q3 this year exceeded 6,000 unique page views.
McNeely, J., Wu, L.T., Subramaniam, G., Sharma, G., Cathers, L.A., et al. (2016). Performance of the Tobacco, Alcohol, Prescription Medication, and Other Substance Use (TAPS) Tool for Substance Use Screening in Primary Care Patients. Annals of Internal Medicine, 2016 Nov 15;165(10):690-699.
Angéline Adam, Robert P Schwartz, Li-Tzy Wu, Geetha Subramaniam, Eugene Laska, Gaurav Sharma, Saima Mili, Jennifer McNeely. Electronic self-administered screening for substance use in adult primary care patients: feasibility and acceptability of the tobacco, alcohol, prescription medication, and other substance use (myTAPS) screening tool. Addict Sci Clin Pract. 2019 Oct 15;14(1):39.
|Number of organizations/individuals with which this data element has been electronically exchanged||5 or more. This data element has been tested at scale between multiple different production environments to support the majority of anticipated stakeholders.|
There are 10 registered users for the TAPS Tool API, and we have received about 5 additional inquiries expressing interest in EHR/EMR system integration. None of the registered users are currently active.
|Restrictions on Standardization (e.g. proprietary code)||None known.|
|Restrictions on Use (e.g. licensing, user fees)||None known.|
|Privacy and Security Concerns||None known.|
|Estimate of Overall Burden||Minimal -- for more information, see “Frequently Asked Questions About Screening” at https://www.drugabuse.gov//taps/#/.
The tool is designed to be brief and should take fewer than 5 minutes to administer, but may be completed quicker if the patient does not endorse recent substance use. Clinicians may wish to identify local providers and or specialty care SUD programs to which to refer patients with higher risk levels well before beginning systematic screening. This will greatly assist with finding a suitable referral when the need arises
|Other Implementation Challenges||There is no additional information on challenges.|